Incidence and prevalence of medication-induced osteoporosis: Evidence-based review

Current Opinion in Rheumatology

Volumn 20, Issue 4, 2008, Pages 435-441

  Allport, Juliette ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BRONCHODILATING AGENT; CORTICOSTEROID; EXEMESTANE; LETROZOLE; MEPREDNISONE; OLANZAPINE; PREDNISONE; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; GLUCOCORTICOID;

ANDROGEN DEPRIVATION THERAPY; BREAST CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LUNG DISEASE; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; VERTEBRA FRACTURE; CHEMICALLY INDUCED DISORDER; EVIDENCE BASED MEDICINE;

EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; OSTEOPOROSIS; PREVALENCE;

EID: 47049124866     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282ff0d6d     Document Type: Review

References (37)

1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777-787.
2. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87:3656-3661.
3. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163:181-186.
4. Shapiro CL. Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol 2005; 23:4847-4849.
5. Pan G, Yang Z, Ballinger SW, et al. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci 2006; 1068:297-308.
6. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167:1240-1245.
7. Abraham G, Paing WW, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 2003; 160:1618-1620.
8. Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 2006; 18:43-48.
9. Backos M, Rai R, Thomas E, et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14:2876-2880.
10. NIH Osteoporosis and Related Bone Diseases. Osteoporosis. 2007; Available at: http://www.niams.nih.gov/Health-Info/Bone/Osteoporosis/default.asp.
11. Poor G, Atkinson EJ, O'Fallon WM, et al. Predictors of hip fractures in elderly men. J Bone Miner Res 1995; 10:1900-1907.
12. Abrahamsen B, Nielsen MF, Eskildsen P, et al. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007; 100:749-754.
13. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007; 190:129-134.
14. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol 2007; 118:338-344.
15. Che M, Ettinger B, Nguyen MT, et al. High-dose corticosteroid exposure and osteoporosis intervention in adults. Ann Allergy Asthma Immunol 2006; 97:497-501.
16. Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005; 52:2485-2494.
17. Walther F, Fusch C, Radke M, et al. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr 2006; 43:42-51.
18. Conway SP, Morton AM, Oldroyd B, et al. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax 2000; 55:798-804.
19. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000.
20. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56:279-284.
21. Cabanillas ME, Lu H, Fang S, et al. Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma 2007; 48:1514-1521.
22. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16:581-588.
23. Zorzon M, Zivadinov R, Locatelli L, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005; 12:550-556.
24. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
25. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23:7897-7903.
26. Lopez AM, Pena MA, Hernandez R, et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005; 16:707-711.
27. Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101:541-549.
28. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment- associated bone loss and fractures among women with breast cancer receiving aroma-tase inhibitors. Clin Breast Cancer 2006; 7:127-132.
29. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
30. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486-492.
31. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559-570.
32. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8:119-127.
33. Anastos K, Lu D, Shi O, et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther 2007; 12:1049-1058.
34. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. Aids 2000; 14:F63-67.
35. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167:188-194.
36. O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005; 25:26-31.
37. di Munno O, Mazzantini M, Sinigaglia L, et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 2004; 31:1305-1309.